Curated News
By: NewsRamp Editorial Staff
November 17, 2026
VolitionRx Expands Fujifilm Deal for Feline Cancer Test in Japan
TLDR
- VolitionRx expands its Fujifilm Vet Systems agreement to include the Nu.Q Vet Feline Test, targeting Japan's nearly 9 million cats for potential revenue growth.
- The expanded agreement covers development and use of the Nu.Q Vet Feline Test, following a canine test launch, with plans for an additional study and launch on the IDS i10 automated analyzer.
- VolitionRx's feline cancer test aims to enable earlier detection of lymphoma in cats, potentially improving outcomes and making cancer screening a routine part of veterinary wellness exams.
- VolitionRx is developing a blood-based feline cancer test for lymphoma, the most common cancer in cats, with high accuracy shown in prototype research.
Impact - Why it Matters
This news matters because it represents a significant step forward in veterinary oncology, particularly for cats, which often suffer from late-diagnosed cancers like lymphoma. By expanding its partnership with Fujifilm Vet Systems in Japan, VolitionRx is bringing a blood-based cancer screening test for felines to a market with nearly 9 million cats, potentially enabling earlier detection and treatment. The use of the automated IDS i10 platform could make cancer screening a routine part of veterinary wellness exams, improving outcomes for pets and providing a new revenue stream for VolitionRx. This expansion not only validates the company's epigenetics-based technology but also addresses a critical unmet need in veterinary medicine, with implications for the broader adoption of liquid biopsy tests in animal health.
Summary
VolitionRx Limited (NYSE American: VNRX), a multinational epigenetics company, has expanded its supply agreement with Fujifilm Vet Systems Co. Ltd. in Japan to include the development and use of its Nu.Q Vet Feline Test. This builds on the July 2024 launch of the Nu.Q Vet Canine Test in Japan, where growing veterinary demand led to the introduction of an automated version earlier this year. The expansion follows research showing high accuracy for a prototype feline assay in detecting lymphoma, the most common cancer in cats. Fujifilm plans to conduct an additional study with veterinary oncologists in Japan.
Volition said the expanded agreement presents a potential revenue opportunity in Japan, where the feline population approaches 9 million. The company is continuing product development of the blood-based feline cancer test, with plans to launch it on the Immunodiagnostic Systems (“IDS”) i10 automated analyzer platform. Volition aims to make cancer screening a routine component of annual veterinary wellness examinations, extending its existing canine testing technology to address the need for earlier cancer detection in cats. To view the full press release, visit: https://ibn.fm/6fgSw.
About Volition: Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life. The contents found at Volition’s website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only. Media Enquiries: Ellen Amonoo, Volition, [email protected]. For further information, visit the company’s website at https://volition.com/.
About InvestorWire: InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge. For more information, please visit https://www.InvestorWire.com. Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer. InvestorWire, Austin, Texas, www.InvestorWire.com, 512.354.7000 Office, [email protected]. InvestorWire is powered by IBN.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, VolitionRx Expands Fujifilm Deal for Feline Cancer Test in Japan
